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Deciphering the mechanism 
of action of 089, a compound 
impairing the fungal cell cycle
Irene Stefanini1,9, Lisa Rizzetto1, Damariz Rivero2, Silvia Carbonell3,4, Marta Gut3,4,  
Simon Heath3,4, Ivo G. Gut3,4, Andrea Trabocchi  5, Antonio Guarna5, Nagwa Ben Ghazzi6,7, 
Paul Bowyer6,7, Misha Kapushesky8 & Duccio Cavalieri  1,2
Fungal infections represent an increasingly relevant clinical problem, primarily because of the increased 
survival of severely immune-compromised patients. Despite the availability of active and selective 
drugs and of well-established prophylaxis, classical antifungals are often ineffective as resistance is 
frequently observed. The quest for anti-fungal drugs with novel mechanisms of action is thus important. 
Here we show that a new compound, 089, acts by arresting fungal cells in the G2 phase of the cell 
cycle through targeting of SWE1, a mechanism of action unexploited by current anti-fungal drugs. The 
cell cycle impairment also induces a modification of fungal cell morphology which makes fungal cells 
recognizable by immune cells. This new class of molecules holds promise to be a valuable source of 
novel antifungals, allowing the clearance of pathogenic fungi by both direct killing of the fungus and 
enhancing the recognition of the pathogen by the host immune system.
Over the past 20 years, the incidence of invasive fungal infections has increased1. While skin and nail infections 
have been estimated to affect ~25% of the total population worldwide, invasive fungal infections are uncommon, 
mainly affecting immuno-compromised patients who become more susceptible to fungal infections than healthy 
individuals2. Although invasive infections have an incidence much lower than superficial infections, the rate of 
mortality associated with invasive fungal infections is of particular concern, since it often exceeds 50% of the 
infected population2 and it is now estimated to be greater than mortality caused by malaria3,4. After the discov-
ery of amphotericin B deoxycholate in the 1950s5, the discovery of new anti-fungal drugs has lagged behind the 
increasing need for their use. Amphotericin B is very effective for the treatment of a wide spectrum of fungal 
infections, but it has shown several side effects6. This led to the advent of new amphotericin B formulations and 
of a few new classes of anti-fungal, such as azoles and echinocandins7. Fungal infections are nowadays mainly 
treated with azole antifungals followed by candins. Yet the use of these new compounds and formulations is not 
sufficient to effectively treat fungal infections, mainly because of the insurgence of resistance in pathogenic fungi8. 
Thus, the quest for new anti-fungal drugs is urgent. For many years the budding yeast Saccharomyces cerevisiae 
has been chosen as one of the best cellular models for high-throughput identification of bioactive compounds 
and for their characterization. By using this approach, it is possible to identify new drugs with novel mecha-
nisms of action. A new interest has grown in anti-fungal drugs able not only to kill the pathogenic fungus, but 
also to facilitate the host immune response9,10. Priming of the host immune response as an adjunct to conven-
tional anti-fungal therapy represents a promising avenue to enhance the activity of antifungals. By exerting a 
direct pharmaco-therapeutic effect, fungal load may be directly reduced by the anti-fungal agent, thus providing 
time for the host to mount an effective immunologic program that will eradicate the invading pathogen without 
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excessive inflammation. Several combined therapies where chemokines and cytokines are used in conjunction 
with classical antifungals have been proposed11. Voriconazole, fluconazole and echinocandins have been shown 
to stimulate the immune response through induction of regulatory chemokine and cytokine expression12–14. 
Here we show the mechanism of action of a new compound, 089 [(7R)-3-benzhydryl-2-oxo-5-phenyl-6,8-dioxa-
3-aza-bicycle[3.2.1]octane-7-carboxyl-ethylamide, Fig. 1a]. This compound was identified in a chemical library 
encompassing small bi-cyclic molecules generated by combining tartaric acid and amino acids (BTAa)15. Our 
previous work showed that, the 089 compound had the highest anti-fungal activity against Saccharomyces cere-
visiae strains (MIC, Minimal Inhibitory Concentration = 0.3 mM15) of the molecules in the library and was thus 
selected for further investigations. Here we show that this compound, by targeting the SWE1 gene, conserved 
among pathogenic and non-pathogenic fungi, induces an impairment of the cell cycle with a consequent modifi-
cation of cell morphology. This effect finally results in an increased recognition of treated fungi by immune cells, 
thus making the 089 chemical class a promising group of antifungals with potential for immune modulation.
Results
Identification of the mechanism of action of the new anti-fungal drug in the model fungus, 
Saccharomyces cerevisiae. To identify the molecular mechanisms underlying the effects induced by the 
anti-fungal drug 089 (Fig. 1a)15, we carried out a combination of analyses in the model yeast S. cerevisiae pro-
viding complementary information. Homozygous and heterozygous barcoded deletion collection sequencing 
was combined with transcriptional analysis and in vivo validation tests (Fig. S1). The heterozygous and homozy-
gous barcoded deletion collections were generated in the model yeast S. cerevisiae and have been widely used 
to identify the mechanism of action of new and well-characterized compounds16. Each strain composing the 
deletion collection is deleted in a single gene, and the deletion is recognizable by the presence of specific DNA 
sequences (the “barcodes”)17. Hence, all the deletion strains can be pooled and treated at once with the compound 
Figure 1. Profiling of the effect of 089. (a) Chemical structure of 089; (b) Fitness defect scores of the (HIP) 
heterozygous deletion strains treated with 089. FD scores were calculated for each deletion strain as the 
difference of the abundance of the strain in the control compared to the treatment. Clearance, used as measure 
of the drug selectivity, was calculated as the difference of the FD of a given strain and the two closest FDs. 
Deletion strains having significant positive FD are potential targets of the compound; black triangles indicate 
the strains having significant FD and high clearance; (c) Effects of several concentrations of 089 on the 
growth of representative heterozygous strains selected based on the HIP results. The percentage of growth 
was calculated as the difference of the treated sample’s OD600 compared to the control OD600 (DMSO- treated 
deletion strain). Vertical bars indicate the standard deviation of three independent biological replicates. 
*Wilcoxon test p < 0.05 between the control and the strain indicated by the asterisk color, corresponding to the 
legend.
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of interest. By treating the heterozygous barcoded deletion collection (HIP, HapoInsufficiency Profiling) with 089, 
we aimed to identify genes encoding proteins targeted by the treatment. In a heterozygous background, strains 
bearing a single copy of the target gene are more sensitive to the compound. Thus, a sub-lethal concentration of 
the anti-fungal is effective only against strains deleted in genes encoding proteins targeted by the anti-fungal. 
Because the deletion of a given gene could per se modify the growth ability of the strain, the results need to be 
compared to a control treatment (DMSO, the solvent used to dissolve the molecule of interest). Hence, we treated 
the deletion collections with a sub-lethal dose of 089 (0.2 mM, previously identified)15 or with a control treatment 
(DMSO), both treated for 20 generations at 27 °C in shaking culture and compared the relative abundances of 
each deletion strain. Fitness Defect (FD) scores were calculated for each deletion strain as the difference of the 
abundance of the strain in the control compared to that in the treatment (see materials and methods for further 
details). Aiming at the identification of targets, we searched for strains having positive FD in the heterozygous 
deletion collection (present at higher numbers in the control than in the treatment samples). 74 heterozygous 
deletion strains showed FD scores significantly different after the 089 treatment compared to the control (Fig. 1b). 
Among the strains having significantly different FD scores, only 14 strains showed positive FD scores, thus being 
candidates as 089 targets (Fig. 1b). To validate the results of the HIP analysis, we separately evaluated the effect 
of several 089 concentrations on the growth of the heterozygous deletion strains showing the highest significant 
FD and the highest clearance (the latter calculated as the difference in FD score between a given deletion strain 
and the deletion strains having the closest FD score) (Fig. 1c and Table S1). The YJL187C (SWE1) deletion strain 
was the most sensitive to the treatment, showing a high growth inhibition at the lowest tested concentration 
(0.1 mM, Mann-Whitney p < 0.05, Fig. 1c), three folds lower than the MIC evaluated for the wild-type strain. The 
morphogenesis checkpoint kinase Swe1p is one of the key regulators of the yeast cell cycle which regulates the 
G2/M transition and several other functions. This protein kinase acts by negatively regulating Cdc28p through 
phosphorylation, thus delaying mitosis and, when over-expressed, leads to cell cycle arrest in the G2 phase18. We 
also observed that the strain deleted in YBR133C (HSL7) showed a significant positive FD score in the HIP assay 
(Fig. 1b), but its killing by 089 was not confirmed in the single-strain assay (Fig. 1c). Hsl7p blocks the mitotic exit 
by means of Swe1p inhibition (by phosphorylation) and prevents Swe1p accumulation and ability to inhibit the 
cyclin complex composed of Cdc28p, Clb1p and Clb2p19.
Homozygous deletion profiling analysis. The treatment of the homozygous barcoded deletion col-
lection (HOP, HOmozygous deletion Profiling) with a sub-lethal concentration of the investigated compound 
(0.2 mM) allows the identification of pathways targeted by the treatment or involved in the response to it. Aiming 
at the assessment of the cell response to the treatment, we treated the homozygous deletion collection as the 
heterozygous deletion collection (see previous paragraph) and searched for strains having significantly different 
FD scores between the treatment with 089 and the control (DMSO). As expected, the number of deletion strains 
having significant FDs identified after the treatment with 089 was higher in the HOP compared to the HIP assay 
(92 strains the first, 74 the latter, Table S1 and Fig. 1b). The list of FDs significantly differing in the treatment 
with 089 compared to the control (Table S2) was analyzed by means of pathway signature analysis, which allows 
determination of gene sets (either pathways or sets of genes regulated by the same transcription factor) that are 
differentially represented in the compared conditions20. Positive HOP FD scores correspond to strains deleted in 
genes involved in the response to the treatment and negative HOP FD scores indicate strains deleted in genes (or 
involved in pathways) targeted by the treatment. Hence, the same interpretation can be used for pathway analysis. 
All the differentially represented gene sets were over-represented (Table S2). Several differentially represented 
gene sets were related to the cell cycle (Fig. 2a), thus supporting the targeting of Swe1p by the molecule: the cell 
cycle as described in the KEGG database21 and the genes regulated by Hog1p and Rme1p transcription factors22. 
In addition, gene sets related to the cell morphology (associated to YBR627W, Gat3p, Dot6p, Hms1p transcrip-
tion factors’ activity, Fig. 2a) were over represented in HOP analysis.
Pathway analysis on S. cerevisiae gene expression. To further contextualize the HIP and HOP 
results, the effect of the compound on the model yeast S. cerevisiae was analyzed at the molecular level through 
gene expression microarray analysis (Table S3). To accomplish this, the S. cerevisiae haploid laboratory strain 
BY4742 was treated with a sub-lethal concentration of 089 (0.2 mM), for 4 hours at 27 °C in shaking and com-
pared the resulting transcriptional profile with the control transcriptional profile (cells treated with DMSO). 
Pathway signature analysis20 was carried out on the transcriptional profile induced by the treatment (Table S3). 
The results indicated impairment of the cell cycle, further supporting the targeting of Swe1p by 089 (Fig. 2b). 
Pathway analysis revealed that 089 allowed cells to proceed through the G1 and S phases and caused a cell arrest 
in the G2 phase (under-expression of genes related to the G1/S transition, to the E2F transcriptional targets at 
G1/S, and to the mitotic cell cycle pathways, Fig. 2b). In addition, a modification of cell morphology pathways 
was observable through pathway analysis, indicating a decrease in glycan structures (under-expression of their 
biosynthesis and over-expression of their degradation) and the inhibition of pseudo-hyphal filamentation or 
flocculation (genes controlled by Hms1p and Sfl1p). Furthermore, genes related to sphingolipid metabolism were 
also found over-expressed in response to the treatment with 089 (Table S3). The low number of gene sets differ-
entially represented after 089 treatment and the fact that they are associated to only three main classes (cell cycle, 
morphology and lipid metabolism) is an indication of the molecule’s selectivity. To assess the novelty of the mech-
anism of action of the new compound 089, we compared the 089 HIPHOP profile with those of 3356 compounds 
published by Lee and coworkers16. The clustering of HIPHOP profiles and the following profiles grouping defined 
through the dynamic branch cutting method highlighted a 089 HIPHOP similarity to 27 HIPHOP profiles of 
the Lee database (Fig. S2). Embedded in the sub-cluster encompassing the 089 HIPHOP, there was a group of 
treatments identified to induce a modification of tryptophan biosynthesis and mitochondrial translation (Table 
www.nature.com/scientificreports/
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S4)16. In addition, only two of the 089 co-clustering treatments have a known target (RER2 for both), coding a 
cis-prenyltransferase involved in dolichol synthesis and participating in endoplasmic reticulum protein sorting16.
Validation and phenotypic effects of Swe1p targeting in S. cerevisiae by the 089 compound. 
HIP, HOP, and transcriptional analyses suggested that 089 impairs the S. cerevisiae cell cycle and arrests cells in 
the G2 phase. To validate this observation, we used flow-cytometry to quantify the DNA content of cells treated 
with 089 compared to the DNA content of control cells (treated with DMSO). To avoid the inclusion of bud-
ding cells in the analysis which would skew the quantification of single-cell DNA content, the DNA content 
was estimated only for cells showing forward and side scatter values similar to those of a culture of the BY4742 
haploid strain. Cells of the haploid laboratory strain BY4742 were treated for 4 hours with a lethal concentration 
of 089 (0.3 mM) and their DNA content was determined by Propidium Iodide labeling in comparison to haploid 
BY4742 untreated cells and diploid cells obtained by crossing the BY4742 and W303 laboratory strains (Table 
1). A significantly increased number of cells bearing a doubled content of DNA (characterizing the G2/M phase) 
was observed after treatment with 089 compared to DMSO (n = 3, 2-tailed t-test p < 0.01). Thus, flow-cytometry 
analysis confirmed that cells treated with the 089 molecule accumulated in the G2/M phase (Fig. S3a). The arrest 
of the cell cycle in the G2/M phase due to an altered Swe1p activity has previously been associated with reduced 
fidelity in bipolar budding23 and to an altered bud morphology24. In accordance with this, cells treated for 4 hours 
with 0.3 mM 089 showed an abnormal bud morphology: they elaborated multiple simultaneous budding events, 
indicating either that daughter cells do not separate after the budding or that multiple daughter cells emerge at 
the same time (Fig. S3b). A modification of cell morphology was also observed by means of pathway analysis on 
the transcriptional profiles induced by 089 treatment (Table S3), and in particular a decrease in glycan structures 
and the inhibition of pseudo-hyphal filamentation or flocculation were observed. To further support these obser-
vations, we evaluated the effects of combined treatments of S. cerevisiae cells with 089 and compounds known to 
modify cell wall composition or structure. We tested the combined effect of 089 with caspofungin (an echinocan-
din, inhibiting β-glucan biosynthesis), clotrimazole (an azole, inhibiting ergosterol biosynthesis), amphotericin 
B (forming pores on the cell membrane), and calcofluor white (binding chitin). BY4742 cells were treated for 
24 hours at 28 °C with a lethal concentration of 089 (0.3 mM) and sub-lethal 089 concentrations (0.2 mM, 0.1 mM, 
and 0.05 mM) alone or combined with lethal or sub-lethal concentrations of the cell wall-affecting compounds 
(Fig. 3). Notably, the combination of the lowest tested 089 concentration (0.05 mM) and the lowest tested caspo-
fungin concentration (0.0315 µg/ml) induced an effect statistically similar to the effect induced by the treatment 
with the lethal 089 concentration (0.3 mM; 2-tailed t-test, FDR > 0.05). A similar effect was observed in the 
089-clotrimazole combined treatments. Nevertheless, the 089-clotrimazole combination was as lethal as 0.3 mM 
Figure 2. Effects of 089 on Saccharomyces cerevisiae cell cycle as indicated by HOP and expression analyses. 
(a) heatmap showing differentially expressed (microarray expression analysis) or differentially represented 
(HOP -Homozygous Profiling- analysis) genes involved in cell cycle, morphology and lipid biosynthesis. Only 
genes significantly differentially represented/expressed, belonging to one of the three gene sets and showing a 
log2(fold change) value higher than 1 or lower than −1 are shown. For graphical representation, values were 
scaled between −1 and 1. FC = Fold Change, ratio; (b) the circle summarizes the 089 effects, found by means 
of HOP and expression analysis, on the S. cerevisiae cell cycle. Gene sets significantly differentially represented 
after the treatment with 089 are reported as capital letters in the scheme and written in the extended form in the 
legend. In the scheme, black arrows pointing up indicate an over represented gene set, black arrows pointing 
down indicate under represented gene sets (Fisher Exact Test p-value < 0.05). In the legend, plus and minus 
indicate over- and under- represented gene sets.
www.nature.com/scientificreports/
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089 only in the presence of 1.5 µg/ml clotrimazole (corresponding to the MIC). On the other hand, combined 
treatment with amphotericin B resulted in i) a reduction of the lethal effect of 0.3 mM 089, ii) a slight decrease of 
the cell growth in presence of 0.2 mM 089 or iii) no variations in the effects induced by lower 089 concentrations 
(Fig. 3). The combined treatment with calcofluor white had a similar effect, reducing the 0.3 mM 089 lethality and 
slightly increasing the effect of lower 089 concentrations. The changes in cell wall composition were also assessed 
by means of calcofluor white staining. BY4742 S. cerevisiae cells were inoculated in YPD supplemented with 
either 0.3 mM 089 or DMSO and treated for 4 hours at 28 °C with shaking. The cells treated with 089 showed a 
reduced labeling with calcofluor white compared to the control, especially when considering emerging new cells 
(Fig. S5).
Swe1p has also been recently shown to positively regulate sphingolipid biosynthesis by phosphorylating and 
inhibiting Orm proteins25. Also in this context, the targeting of SWE1 by 089 was confirmed by the observation 
that, after a 24 hours treatment with 0.3 mM 089, ceramides accumulated over free fatty acids, indicating an 
induction of de novo sphingolipid biosynthesis (Fig. S3c). We note that this effect was also observed at the path-
way level through transcriptional analysis (Table S3).
The 089 anti-fungal activity against pathogenic fungi. The increasing emergence of drug-resistant 
pathogenic fungal strains led us to consider the potential of 089 to inhibit the growth of clinically important 
pathogens. Hence, we assessed the effect of the treatment with 089 at various concentrations (0.3 mM, 0.2 mM, 
0.1 mM) on the survival of Candida albicans and C. glabrata cells treated for 4 hours in YPD at 28 °C with shak-
ing. After 4 hours treatment, we calculated the percentage of surviving cells as described in methods section. 
Following this assessment 100 live cells were plated onto YPD agar medium. After 4 days the CFU % (Colony 
Forming Units %) was calculated as the number of colonies formed by treated cells compared to the number 
of colonies formed by control cells. Each concentration of 089 induced a significant decrease in CFU in all the 
assayed yeast species (ANOVA test, Fisher post-hoc, p < 0.00001), indicating that 089 was effective also against 
pathogenic yeasts (Fig. 4a). The effects of 089 were also investigated using three different strains of Aspergillus 
fumigatus (Fig. S5a): a wild-type strain, A1160, and two azole-resistant strains, CYP51KO (deleted in the cyp51A 
gene and azole hyper-sensitive) and RFLS58 (an azole resistant environmental isolate). A. fumigatus conidia were 
inoculated at 2.5 × 105 spores/ml in MOPS-buffered RMPI 1640 medium supplemented with 2% glucose and 
several concentrations of 089 (serial dilutions from 1 mM to 0.025 mM) or DMSO as control. The treatment was 
carried out for 48 hours in static at 37 °C. At the end of the treatment, cultures were microscopically inspected to 
evaluate the cell survival and the cell morphology. The MIC (Minimum inhibitory concentration, the lowest con-
centration inducing fungal death) evaluated for azole-resistant strains CYP51ko was 1 mM, while for the A1160 
reference strain was even higher (Fig. S5a). Nevertheless, a strong inhibition of the conidia germination induced 
by 089 was observable in all the tested strains (Fig. 4b). The MEC (Minimum Effective Concentration), consid-
ered as the minimal concentration inhibiting hyphae formation, differed among the tested A. fumigatus strains. 
The CYP51ko strain was the most sensitive (MEC = 0.3 mM) and the other azole-resistant strain (RFLS58) was 
Strain Species Genotype Characteristics Used in the assay:
BY4742 S. cerevisiae MATα his3Δ1 leu2Δ0 lys2Δ0 Laboratory/reference strain
1.  background for heterozygous and 
homozygous deletion collections used for 
HIP and HOP analyses.
2.  Transcriptomic analysis (microarray 
hybridization)
3.  phenotype validation (DNA content, 
budding morphology, phospholypid 
quantification, DC-binding)
BY4742 SWE1::KANMX4 S. cerevisiae MATα his3Δ1 leu2Δ0 lys2Δ0 SWE1::KANMX4 Laboratory/reference strain Target validation
BY4742 HSL7::KANMX4 S. cerevisiae MATα his3Δ1 leu2Δ0 lys2Δ0 HSL7::KANMX4 Laboratory/reference strain Target validation
BY4742 RNY1::KANMX4 S. cerevisiae MATα his3Δ1 leu2Δ0 lys2Δ0 RNY1::KANMX4 Laboratory/reference strain Target validation
BY4742xW303 S. cerevisiae
leu2Δ0/leu2-3,112 TRP1/trp1-
1 can1-100 ura3Δ0/ura3-1 
ADE2/ade2-1 his3Δ1/his3-
11,15 LYS2/lys2Δ0 [phi+]
Laboratory/reference strain Reference for DNA content determination
YUC22 C. glabrata Wild-type Clinical isolate MIC evaluation in Candida spp.
SC5314 (ATCC MYA-2876) C. albicans Wild-type Laboratory/reference strain MIC evaluation in Candida spp.
A1160 A. fumigatus akuB (KU80)-delta pyrG1 MAT1-1 Laboratory/reference strain
1. MIC evaluation in Aspergillus spp.
2. transcriptomic analysis (RNAsequencing)
CYP51KO A. fumigatus (cyp51A)-delta akuB (KU80)-delta pyrG1 MAT1-1 Azole hyper-sensitive MIC evaluation in Aspergillus spp.
RFLS58 A. fumigatus Wild-type Clinical isolate resistant to azoles MIC evaluation in Aspergillus spp.
K562 (ATCC CCL-243) H. sapiens Wild type Immortalised myelogenous leukemia 089 toxicity on mammalian cells
Table 1. Yeast, and fungal strains and mammalian cell lines used in this study.
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the less sensitive to the treatment (MEC = 0.5 mM, Fig. S5a). To further characterize the effect of 089 on A. fumig-
atus, we first evaluated the internalization of the compound. We observed the localization of microscopic auto 
fluorescent drug particles before and after a PBS washing of treated cells (Fig. 4c). Before washing, drug granules 
were evident on the surface of conidia and germling cells excluding the view of cell contents, whereas after wash-
ing, the fluorescent compound was localised within the cell cytoplasm thus showing the ability of the compound 
to enter the cells (Fig. 4c). To further validate the inhibitory effect of 089 on A. fumigatus conidia germination, 
we measured swelling of A1160 A. fumigatus spores exposed to the compound (Fig. 4d). The area and volume of 
A1160 conidia treated with 0.4 mM 089 or with DMSO as control was measured in Sabouraud medium at 37 °C 
over a time course of 6 h. In the control treatment spores swelled evenly and continuously, but neither volume or 
area of conidia treated with 089 changed during the treatment (Fig. 4d). Treated spores did not germinate. (Fig. 
4d). Since A. fumigatus often initiates infections in hyphal form, we also evaluated the effect of the compound 
on A. fumigatus hyphae (Fig. 4e). If the cell cycle inhibition induced by 089 observed in S. cerevisiae cells is con-
served in A. fumigatus, fungal cells treated with the compound should not be able to grow and form multinucleate 
cells. Hence, we evaluated the number of nuclei in an A1160 strain expressing a GFP labelled Histone 1 protein 
(H1-sGFP). H1-sGFP treated with 089 compared to the control treatment (DMSO). Conidia were grown in 
Sabouraud media for 6 hours, allowing conidial germination. Afterwards, cells were treated with 0.4 mM 089 or 
with DMSO and images were acquired after 90 minutes every 10 minutes. The growth of hyphae treated with the 
089 compound was clearly inhibited, as indicated by the fact that treated cells did not form elongated, polynucle-
ated cells as in the control. Additionally, nuclei did not divide in cells treated with 089 (Fig. 4e and Supplementary 
Movie S1–S3).
Figure 3. Effects on S. cerevisiae growth of 089 in combination with compounds known to perturb the cell wall. 
BY4742 S. cerevisiae cells were treated with lethal (MIC, 0.3 mM) and sub-lethal (0.2 mM, 0.1 mM, 0.05 mM) 
concentrations of 089 combined with lethal and sub-lethal concentrations of caspofungin (a) clotrimazole (b) 
amphotericin B (c) and calcofluor white (d). Treatments were carried out in YPD for 24 hours at 28 °C with 
shaking. Growth was quantified by measuring the OD600 (Optical Density at 600 nm). For each treatment, 
growth % was calculated as the percentage of OD compared to the control (treated with DMSO). 2-tailed t-test 
was performed to evaluate differences between the effect of each combined treatment and the effect of the 
089 lethal concentration (0.3 mM) and p-values were FDR corrected. *Treatments not significantly changing 
compared to the 089 lethal concentration (FDR > 0.05).
www.nature.com/scientificreports/
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The effects of 089 on Aspergillus fumigatus at the molecular level. The effects of 089 exposure on 
the A. fumigatus wild-type strain were investigated at the molecular level by means of RNA-sequencing analysis 
and compared to the transcriptional profile of a control culture (treated with DMSO). Conidia were inoculated 
at 2.5 × 105 conidia/ml in MOPS-buffered RPMI 1640 + 2% glucose supplemented with either 0.1 mM 089 or an 
equal volume of DMSO. After 4 hours of static growth at 37 °C, mycelium was frozen in liquid nitrogen, ground to 
a fine powder then RNA was extracted, and Illumina sequenced. Genes whose expression significantly changed 
between the treated and the control cultures (FDR < 0.05) were identified as DEGs (Differentially Expressed 
Genes). We found 436 DEGs compared to the control. Of these, 209 were under-expressed (their transcripts are 
more abundant in control samples than in treated samples, 166 with log2ratio < −2) and 227 were over-expressed 
(their transcripts are more abundant in the treated samples than in the control samples, 95 with log2ratio > 2) 
(Table S5). Considering the over-expressed genes, we found an enrichment in Gene Ontologies (GO) related 
to iron starvation response, response to drug, iron and phosphate transmembrane transport, and secondary 
Figure 4. The effects of 089 on pathogenic fungi. (a) Effects of 089 on Candida spp. cells; 5 × 106 cells/ml of S. 
cerevisiae (black bars), Candida albicans (grey bars) and C. glabrata (white bars) cells were treated with several 
concentrations of 089 or DMSO as control (UT). After 4 hours of treatment in YPD at 30 °C, 100 live cells 
were plated onto solid YPD and formed colonies were counted after at least 4 days. Values indicate Colony-
Forming Units (CFU) average + SD (n = 3), ANOVA test was carried out, using Fisher as post-hoc test to 
compare treatments, *p < 0.0001 (b) Representative images of the 089 effects on hyphal formation. Aspergillus 
fumigatus spores (2.5 × 105 spores/ml in RPMI 1640 medium + 2% glucose) were treated with serial dilution 
of 089 ranging from 1 mM to 25 µM were added in 96-well plates containing. The effects were microscopically 
inspected after 48 hours. The images show the effects of 0.4 mM 089 (concentration at which all the strains 
showed the phenotype) or DMSO as control. (c) Internalization of 089 drug granules within the fungal conidia/ 
germling was evaluated by labelling drug granules approximately 30 minutes post treatment. The localization 
of drug granules was assessed before and after washing twice the treated cells with PBS. Images were acquired 
before and after washing. White arrows refer to drug granules, black arrows refer to conidia/ germling cell wall. 
(d) Effects of 089 on A. fumigatus conidia germination. The volume and area of conidia treated with 0.4 M 089 
or with DMSO as control were measured using Imaris software (Bitplane, UK) of a confocal acquisition time 
lapse over 6 hours. (e) Effects of 089 on A. fumigatus cells growth – hyphal elongation. An A1160 A. fumigatus 
strain expressing the labelled Histone 1 protein (H1-sGFP) was used to evaluate the effect of the treatment 
on hyphal elongation, indicated by the formation of polynucleated cells. H1-sGFP conidia were grown in 
Sabouraud medium for 6 hours at 37 °C, then germlined cells were treated with 0.4 mM 089 or with DMSO as 
control. After 90 minutes treatments, images were acquired each 10 minutes.
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metabolite biosynthesis (Table S6). These processes are known to be involved in a feedback loop regulation 
of the MAPK cell wall integrity pathway which is also involved in the regulation of phenotypes such as radial 
growth and conidiation26, thus possibly explaining the observed inhibition of A. fumigatus spore germination. By 
inspecting the phenotypic effects of the treatments on A. fumigatus cultures we observed an evident impairment 
of hyphae formation (Fig. 4c). Hence, we wondered whether this effect was also observable at the molecular level. 
To evaluate this, we compared the transcriptional profile induced by 089 with a set of transcriptional profiles 
obtained in A. fumigatus cells at different stages of the asexual cycle27, namely conidia (con), germinating conidia 
(GermCon) and hyphae (Hyph). To generate this dataset, Hagiwara and colleagues27 obtained DEGs by compar-
ing the genes’ expression levels in: i) A. fumigatus conidia against hyphae (Con_vs_Hyp), ii) conidia against ger-
minating conidia (Con_vs_GeC), or iii) germinating conidia against hyphae (GeC_vs_Hyp). The transcriptional 
profile of cells treated with the 089 compound clustered with the GeC_vs_Hyp profile, obtained by comparing 
germinating spores against hyphae (Fig. 5a). Hence, this similarity supported what observed at the phenotypic 
level (Fig. 4c). We went further and searched for groups of genes whose expression level was similar in the 089 
treatment and in the GeC_vs_Hyp comparison but was the opposite in the Con_vs_GeC and Con_vs_Hyp pro-
files (Fig. 5a). We found two relevant sub-groups of genes: the first, indicated with “+” in Fig. 5a, was composed 
by genes over-expressed in the 089 treatment and in the GeC_vs_Hyp profiles and under-expressed in the Con_
vs_Hyp and Con_vs_GeC profiles; the second, indicated with “−” in Fig. 5a, encompassed genes under-expressed 
in 089 and GeC_vs_Hyp profiles and over-expressed in Con_vs_Hyp and Con_vs_GeC profiles. Notably, the first 
set of genes (overexpressed in 089 and GeC_vs_Hyp and under-expressed in Con_vs_Hyp and Con_vs_GeC), 
was enriched in GOs related to ribosomes and to rRNA processing, synthesis and modification (Fig. S5b).
The effects observed at the molecular and phenotypic levels, both suggesting an impairment of asexual cell 
cycle progression in A. fumigatus and correspond with the impairment of cell cycle through Swe1p targeting 
observed in S. cerevisiae. To translate the 089 target identified in S. cerevisiae in opportunistic fungal infections 
we looked at the presence of SWE1 in common fungal pathogens. Both Candida glabrata and C. albicans bear 
orthologs of the candidate target SWE1 (CAGL0K00693g and C1_10010C_A, respectively, Fig. S6). Swe1p in 
C. albicans was shown to be required for full virulence, but not for filamentous growth. A. fumigatus contains 
an uncharacterized protein, Afu2g07690, with the highest sequence similarity to the S. cerevisiae Swe1p (the 
Figure 5. The effects of 089 on Aspergillus fumigatus and on the binding of dendritic cells. (a) Comparison 
of the transcriptional profile induced by 089 with the profiles of germinating conidia compared to hyphae 
(GeC_vs_Hyph), of conidia compared to hyphae (Con_vs_Hyph) and conidia compared to germinating 
conidia (Con_vs_GeC). Samples and genes distances were calculated with the Manhattan method and clustered 
with the Ward method. (b) Ability of dendritic cells (DC) to bind fungal cells treated with 089 or with DMSO 
(control). DC were differentiated from healthy donors PBMCs isolated monocytes and exposed to FITC-
labelled fungi (stimuli:DC ratio 5:1) for 30 minutes at 37 °C. DCs were labelled with anti-CD11c-PE. The 
binding of DCs to fungi was measured by flow cytometry. *Mann-Whitney p < 0.0001.
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phylogenetic tree of the fungal orthologues is shown in Fig. S6). Despite SWE1 having two known homologs in 
humans (WEE1 and WEE2), 089 showed a moderate toxicity on mammalian cells, with none of the 089 tested 
concentrations significantly reducing cell survival (Fig. S7).
Effects of 089 on fungal recognition by dendritic cells. Several pathogenic fungi (i.e. Candida 
spp.) switch their phenotype to invade the host tissue, evade the host immune response and shift it towards 
anti-inflammatory response28. Since 089 was shown to alter fungal ability to form hyphae which are more easily 
recognized by the host immune system, we investigated whether this effect could in turn modify the recogni-
tion of treated fungal cells by immune cells. We thus compared the in vitro ability of human monocyte-derived 
dendritic cells (DCs) to recognize and bind 089 treated S. cerevisiae, C. albicans and A. fumigatus cells. Aiming 
at observing potential improvements in the receptor recognition of viable yeast and fungal cells S. cerevisiae, 
C. albicans and A. fumigatus cells were treated with sub-lethal concentrations of the 089 compound (0.2 mM) 
for 4 hours. S. cerevisiae and C. albicans cells were treated in YPD at 28 °C with shaking, A. fumigatus cells were 
treated in MOPS-buffered RPMI medium at 37 °C in static. After the treatment, yeast and fungal cells were 
FITC-labeled and their binding (or internalization) by DC was measured through flow-cytometry (see materials 
and methods section for further details). DCs were able to bind or internalize a higher percentage of both C. albi-
cans and A. fumigatus cells treated with 0.3 mM 089, compared to the same fungal cells exposed to DMSO only 
(Mann-Whitney p < 0.05, Fig. 5b).
Discussion
The parallel utilization of several tools in the model yeast S. cerevisiae allowed the discovery of the mechanism of 
action of the new anti-fungal drug 089. We took advantage of the heterozygous barcoded deletion strain collec-
tion to identify drug targets and to observe affected and response pathways as well as using transcriptional pro-
filing to uncover effects of the drug at the expression level in the entire cell. The combination of these techniques 
gives a complete picture of the effects induced by 089 treatment. The restricted number of potential targets iden-
tified by mean of HIP analysis may predict a high level of selectivity of the molecule. In confirmation the pathway 
level analysis only indicated effects directly associated to SWE1 targeting. The anti-fungal 089 acts on Swe1p, 
which controls cell cycle progression by delaying the G2/M transition through phosphorylation of Cdc28p. Both 
the phenotype and pathway analyses strongly support the Swe1p targeting by 089. While the deletion of the 
identified 089 target SWE1 induces an altered cell cycle kinetics with progression through the G2/M phase tran-
sition29, Swe1p over-expression induces cell arrest in G2/M (Fig. S3a)30. Hence, it could be hypothesized that 089 
induces Swe1p activation. To note, the hypothesis that 089 activates Swe1p was further supported by the observa-
tion that the heterozygous HSL7 gene deletion strain showed a significantly positive FD after treatment with 089 
(Fig. 1b). One of the functions of Hsl7p is to clear Swe1p from the cytosol. Thus, in the HSL7 heterozygous dele-
tion strain, Swe1p accumulates in the cytosol, resulting in an effect similar to the one induced by 089. The arrest 
of the cell cycle in the G2/M phase caused by Swe1p over-expression has been associated to a reduced fidelity in 
bipolar budding23 and to an altered bud morphology24. The activation of Swe1p by 089 was further confirmed 
by the observation of the accumulation of ceramides over free fatty acids, indicating an induction of de novo 
sphingolipid biosynthesis (Fig. S3c). The potential counter-action of 089 and amphotericin B (especially at the 
089 MIC, 0.3 mM) could be ascribed to the fact that amphotericin B acts by forming pores on the cell membrane 
and may be sensitive to the lipid/sphingolipid ratio. The observation that calcofluor white cell wall labeling of S. 
cerevisiae cells treated with 089 was reduced compared to the control treatment may suggest interplay between 
chitin synthesis and Swe1p, especially during early growth stages. Furthermore, the astonishingly high synergis-
tic effect of 089 with caspofungin could be the result of a similar modification of the cell wall β-glucans content. 
Hence, the effect of 089 on Swe1p leads to a modification of cell morphology, observed both in S. cerevisiae and 
in A. fumigatus.
The HIPHOP profile induced by 089 treatment was similar to the HIPHOP profile induced by other chem-
icals16, but the mechanism of action of these compounds was unknown. In addition, the 089 HIPHOP profile 
clusters separately from the profiles of classical antifungals, confirming that this molecule acts through different 
mechanisms and does not trigger a response similar to the one induced by known antifungals in yeast cells. 
The 089 HIPHOP profile was similar to the HIPHOP profiles induced by two compounds (SGTC_1882 and 
SGTC_10) known to target the RER2 gene, involved in dolichol biosynthesis. Dolichol is one of the building 
blocks of membrane structure, hence, a defect in the synthesis of this acid, such as that induced either by the dele-
tion of the RER2 gene31 or by its inhibition caused by treatments with SGTC_1882 and SGTC_1016, can trigger 
a downstream modification of cell morphology similar to that observed during treatment with 089. Concerning 
the other treatments clustering with 089, none of them was identified to have a specific target by Lee and col-
leagues16, probably because the Lee study was carried out on a smaller number of heterozygous deletion strains 
(only those deleted in essential genes) compared to the comprehensive pool used in the present work. It is thus 
possible that these compounds act on targets similar to that of 089, whose target, SWE1, was not included in 
Lee and co-workers’ heterozygous deletion collection. In general, 089 shows a HIPHOP profile different from 
common antfungals including several azoles, amphotericin and caspofungin. Changes in fungal cell morphology 
and hyphae formation that reveal fungal components to immune receptors are crucial for the ability of the host 
immune system to respond to the pathogen. Indeed, fungal cells treated with 089 appear to be recognized and 
bound by immune cells at higher frequency than untreated cells. The increased binding by dendritic cells could be 
the result of either the inability of treated Candida spp. and A. fumigatus cells to initiate hyphal growth or the cell 
wall re-arrangement caused by 089. However, we observed that the binding of dendritic cells to S. cerevisiae cells 
was not improved after the treatment with 089. The S. cerevisiae interaction with dendritic cells has been shown 
to be mediated by the exposure of specific cell wall components, rather than by the yeast morphology32. Hence, 
these results suggest that the inability to initiate hyphal growth is the main factor responsible for the increased 
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recognition of Candida spp. and A. fumigatus cells. Several pathogenic fungi (i.e. Candida spp. and Aspergillus 
spp.) switch their phenotype to invade the host tissue, evade the host immune response and shift it towards 
anti-inflammatory response28, thus 089 could represent a promising compound to boost the immune response or 
synergistically act with the host immune response in eradicating fungal infection.
Methods
Strains used in this study. Yeast and fungal strains and the mammalian cell line used in this study are listed 
in Table 1. The Saccharomyces cerevisiae heterozygous and homozygous diploid barcoded deletion collections 
were generated in the BY4742 genetic background (Invitrogen). Transcriptional analyses on S. cerevisiae were 
carried out on the BY4742 laboratory strain. The validation of the 089 target was carried out on single strain 
cultures of the BY4741 strain deleted in either the HSL7, the SWE1 or the RNY1 genes, which were knocked out 
through replacement with the KANMX4 cassette conferring resistance to geneticin (Invitrogen). As reference for 
DNA content quantification through flow-cytometry, the haploid BY4742 and the diploid BY4742xW303 strains 
were used. The Candida albicans SC5314 (ATCC MYA-2876) reference strain, the C. glabrata YUC22 (a clinical 
isolate) were used to evaluate the 089 MIC in pathogenic yeasts (Table 1). Three strains of Aspergillus fumigatus 
from the Bowyer lab collection were used to evaluate the 089 effect on the pathogenic fungus (Table 1): A1160, a 
reference strain (akuB (KU80)-delta pyrG1 MAT1-1); CYP51, an azole-resistant strain derived from the reference 
A1160 strain by deleting the cyp51A gene ((cyp51A)-delta akuB (KU80)-delta pyrG1 MAT1-1); RFLS58, a clin-
ical isolate resistant to azoles. To evaluate the 089 cytotoxicity on mammalian cells, the K562 (ATCC CCL-243) 
human cell line was used (Table 1).
Growth media and conditions. The S. cerevisiae and Candida spp. strains were grown and treated at 27 °C 
with shaking in YP (1% w/v Yeast Extract, 2% w/v Peptone) supplemented with 2% w/v glucose. Before treat-
ments, yeast cells were grown over night in the same medium and environmental conditions as the treatment 
experiment. Treatments with the compound (or with DMSO as control) were carried out on cells inoculated at 
5 × 106 cells/ml concentration in YPD and treated in shaking at 27 °C.
Aspergillus fumigatus was grown on Sabouraud agar (1% w/v Peptone, 4% w/v glucose, 2% w/v agarose), at 
37 °C. Conidia were collected from Sabouraud agar cultures using PBS + 0.1% Tween, avoiding collection of 
mycelial fragments and hyphae. The sample was filtered with a sterile filter with a pore diameter of 11 µm to 
remove hyphal fragments. Treatments with the compound were carried out in MOPS-buffered liquid RPMI 
1640 medium (Euroclone) supplemented with 2% w/v glucose. The K562 cell line was grown in RPMI 1640 
(Euroclone) supplemented with glutamine (Sigma Aldrich), penicillin and streptomycin (Sigma Aldrich), and 
10% heat-inactivated fetal calf serum (Hyclone). The compound 089 ((7R)-3-benzhydryl-2-oxo-5-phenyl-
6,8-dioxa-3-aza-bicycle[3.2.1]octane-7-carboxyl-ethylamide, MW = 442.51)15 was diluted in DMSO (DiMethyl 
SulfOxide) and added to the medium at the chosen concentration.
Evaluation of the 089 effects on pathogenic yeasts and fungi. The Candida spp. strains were grown 
overnight in YPD medium and then inoculated in fresh medium at a final density of 5 × 106 cells/ml. The 089 
compound was added to the medium at various concentrations (0.3 mM, 0.2 mM, 0.1 mM), DMSO was used as 
control. After 4 hours of treatment at 27 °C with shaking, the Candida spp. cells survival was evaluated with the 
Live/dead® Yeast Viability Kit (Life technologies), as indicated by the manufacturer. Candida spp. cells CFU% 
(Colony Forming Units percentage) was evaluated by plating in YPD agar 100 treated live yeast cells and counting 
colonies formed after at least 4 days. A. fumigatus treatments were performed following the EUCAST protocol33. 
A. fumigatus spores were collected from solid Sabouraud cultures using PBS + 0.1% Tween, avoiding mycelium 
fragments and hyphae collection. 2.5 × 105 spores/ml were inoculated in MOPS-buffered RPMI 1640 medium 
(Euroclone) supplemented with 2% w/v glucose. The effects of serial dilution of 089 ranging from 1 mM to 25 µM 
were assessed in 96-well plates using DMSO as control. Cultures were microscopically inspected after 48 hours of 
static growth at 37 °C. The treatment’s effects were read visually by recording the degree of growth for each well. 
The minimum effective concentration (MEC), defined as the lowest concentration of drug that results in macro-
scopic changes in filamentous growth to microcolonies or granular growth when compared with growth control 
wells, was evaluated for each A. fumigatus strain. For graphical reporting, the effect was scored as follows: 0 if all 
the cells were dead, 1 if no effects were observed compared to the control; between 0.25 and 0.75 for increasing 
hyphae formation inhibition.
HIP HOP analyses. Both the homozygous and heterozygous barcoded-deletion pools (Table 1) were thawed 
and grown in YPD at 27 °C for 5 generations to allow cells to recover from freezing. Cells were then inoculated in 
6 wells plates at 0.062 OD600 in YPD supplemented with 1% DMSO or 0.2 mM 089 (a sub-lethal compound con-
centration). Cells kept grown at 28 °C with shaking. Every five generations, 600 µl of the cultures were harvested 
and re-suspended with the same volume of YPD supplemented with the appropriate volume of DMSO or drug. 
After the 20th generation, cells were harvested, and genomic DNAs were extracted using QIAamp DNA Mini 
Kit (Qiagen) following manufacturer’s instructions. Three independent biological replicates were carried out for 
each treatment. Barcodes amplification was carried out as described in Smith et al.34 and detailed in Fig. S9. Three 
independent replicates were carried out for each treatment. Raw data were normalized and HIPHOP profiles were 
identified as previously described16. To quantify the sensitivity of the deletion strains to the compound, we calcu-
lated for every deletion strain a robust Z score (Fitness Defect score, FD), standardized to allow the comparison of 
different profiles16. Aiming at this, the log2ratio was calculated for each strain as in equation [1].
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where medianR is the median among biological replicates and MAD is the Mean Absolute Deviation.
The concept of “clearance” was defined by Lee et al.16 and identifies hits that are substantially more significant 
than all other hits. After ordering the strains according to their FDs, the clearance is calculated as the difference 
of the FD of a given strain and of the closest strains. To identify strains significantly differing between the con-
trol and the treatment samples, we assumed that the FD scores followed a normal distribution in a screen and 
we calculated the probability that the given strain is an outlier in this distribution (one-sided p-value). Pathway 
analysis on HIP and HOP profiles was carried out by applying the Fisher’s exact test with EuGene analyzer on 
the list of significant strains20. Read counts of identified barcodes for each experiment were submitted to Array 
Express (E-SYBR-6) with the following sample names. 089_HIP: B722, B726, B730; DMSO_HIP: B721, B725, 
B729; 089_HOP: B695, B699, B703; DMSO_HIP: B692, B696, B700.
HIP HOP meta-analysis. As an external dataset, the HIPHOP profiles produced by Lee and co-workers 
were downloaded from http://chemogenomics.pharmacy.ubc.ca/HIPHOP/16. The HIPHOP profiles were com-
posed by strains deleted in essential genes in the heterozygous background and by strains deleted in non-essential 
genes in the homozygous background. Since our pools were composed by higher numbers of strains, we sub 
- divided them to make the profiles comparable. Then, the co-inhibition was calculated as described by Lee et 
al.16. The HIPHOP profiles are composed by significant FD scores (FD scores with p-values > 0.05 were replaced 
with 0), then the co-inhibition was calculated as the Pearson correlation between every couples of profiles. The 
significance of the correlation was estimated by using the Student’s t-distribution method. The clustering of pro-
files was then obtained by applying the Ward.D method of the hclust r function on the distances described as 
(1-coinhibition)35. Sub-clustering was identified in the obtained dendrogram using a dynamic branch cutting 
method by using the cutreeDynamic function of the dynamicTreeCut r package with the non-default parameter 
settings minimum cluster size = 3 and deepSplit = 436.
Microarray transcriptional analysis. BY4742 S. cerevisiae cells were grown overnight in YPD medium. 
The day after, 1 × 109 cells were inoculated in 10 ml of fresh YPD supplemented with 0.2 mM 089 (sub-lethal con-
centration) or with DMSO. Cell cultures were incubated at 28 °C with shaking for 4 hours, then nitrogen frozen. 
RNA extraction was carried out as previously described15. Three independent biological replicates were carried out 
for each treatment. For hybridization onto Agilent 015072 Yeast Oligo Microarray 4 × 44 K 60mer oligonucleotide 
arrays (G2519F, Agilent), 300ng of total RNA were processed with the Agilent QuickAmp Labeling Kit, accord-
ing to the manufacturer’s instructions. Fluorescent cDNA bound to the microarray was detected with a GenePix 
4000B microarray scanner (Axon Instruments), using the GenePixPro6.1 software package to quantify microarray 
fluorescence. Data were normalized using the limma R package37 and DEGs (Differentially Expressed Genes) were 
identified with the RankProduct R package38. Raw and normalized data were submitted to GEO (GSE42418).
Target validation – 089 effects on single cultures of S. cerevisiae deletion strains. Pure cul-
tures of the heterozygous strains deleted in genes selected as potential 089 targets were grown in an overnight 
pre-culture in liquid YPD. Then, 105 cells/ml were inoculated in 96-well plates in fresh YPD supplemented with 
either various concentrations of 089 (0.1 mM, 0.2 mM, 0.3 mM, 0.4 mM, 0.5 mM) or a corresponding volume of 
DMSO. The Optical Density (OD) was then measured every two hours. The percentage of growth was calculated 
as the difference of the treated culture’s OD and the control culture’s OD at the stationary phase (24 hours after 
the inoculum) divided by the control culture’s OD. Mann-Whitney test was carried out searching for significant 
differences between controls and treatments.
Target validation – quantification of DNA content in S. cerevisiae. The cell cycle of BY4742 cells 
treated for 4 hours with 0.3 mM 089 at 28 °C with shaking was assessed by DNA content determination using 
Propidium Iodide (PI) staining and flow cytometry as previously described39. Control cells were treated with 
equal volumes of DMSO. As reference, Nitrogen starved haploid BY4742 cells (1 N) or BY4742xW303 diploid 
cells (2 N) at the exponential growing phase were used40. Fixation and PI staining were carried out as previously 
described41. Events were sub-selected (gated) when showing similar forward scattering (proportional to the cell 
size) and side scattering (proportional to cell complexity) values similar to untreated reference yeast cultures. In 
addition, cells were further selected according to the distribution of events in the plot of pulse area versus pulse 
width, allowing the elimination of overlapping doublet events, as previously described42.
Target validation – quantification of total cell lipid in S. cerevisiae. To quantify the total amounts of 
ceramides and fatty acids, cells treated for 24 h with 0.3 mM 089 or with DMSO as control were pelleted, washed 
with water, Nitrogen-frozen then dried. The quantification was carried out in three independent biological 
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replicates. Cells were subjected to lipid and fatty acids extraction as previously described43. Briefly, 2 g harvested 
cells were mixed with 1 ml methanol. Cells were disrupted by adding 2 g of glass beads and vigorously shaking 
for 4 periods of 30 s with 30 s cooling in dry ice intervals. 2 ml chloroform were added to the supernatant and the 
suspension was stirred for 1 h at room temperature. The organic phase was then transferred in a new tube where 
1 ml of 0.034% MgCl2 solution was added. The mix was stirred for 10 min, then the aqueous phase was removed, 
and the organic phase was washed with 1 ml of 2 N KCl/methanol (4:1. v/v). The mix was centrifuged, and the 
resulting organic phase was washed with a solution of chloroform/methanol/water (3:48:47; per volume). The 
mix was centrifuged, and the solvent of the organic phase was evaporated in a speed vacuum at 55 °C. The lipid 
film was finally dissolved in 0.5 ml chloroform/methanol (2:1, v/v), tightly sealed and stored at −20 °C. Extracted 
lipids and fatty acids were spotted on a silica TLC plate, which was developed as previously described44. Briefly, 
polar lipids were separated by developing the chromatogram in a saturated chamber in chloroform-methanol/
water (65:30:5, v:v:v). The solvent front was allowed to migrate 4 cm from the lower edge of the plate. The solvent 
was evaporated, and the plate was further developed in n-hexane-diethyl ether-acetic acid (80:20:1.5, v:v:v) to 
separate neutral lipids. Lipids were visualized by spraying plates with 20% ethanolic phosphomolibdic acid and 
heating at 180 °C for 10 min. Hence, lipids were visualized as dark spots at different distances from the lower edge 
of the plate. Palmitic acid, stearic acid and non-hydroxy fatty acid ceramide standards were purchased by SIGMA 
and used as reference to identify the lipid classes present in the samples (by comparing the distance from the 
lower edge of the plate). Lipids were quantified by measuring the area of the corresponding spot.
Target validation – effects of 089 on the S. cerevisiae cell wall organization. To further validate 
the effects of 089 on the S. cerevisiae cell wall composition, the chitin distribution in the cell wall was evaluated 
by means of staining with calcofluor white. BY4742 cells from an over-night culture were inoculated (5*106 cells/
ml) in fresh YPD medium supplemented with 0.3 mM 089 (lethal concentration) or with DMSO (control). After 
four hours treatment, cells were washed with sterile water, the pellet was dissolved in 15 µl of sterile water and the 
cells were stained with calcofluor white (0.1 µg/ml). After one-minute incubation, cell membranes were visualized 
at a 100× magnification. Three independent biological replicates were carried out. The images of 10 randomly 
selected fields per replicate were captured.
Assessment of the effects of anti-fungal combinations. To further explore the effect of the 089 com-
pound, its effect on the survival of the laboratory S. cerevisiae strain BY4742 was evaluated in combination with 
antifungals modifying the yeast cell membrane. Aiming at this, the effects of all the combinations of four 089 
concentrations (0.3 mM. 0.2 mM, 0.1 mM and 0.05 mM) and four concentrations of compounds impairing the 
cell membrane or wall composition were evaluated. The tested known compounds were: caspofungin (an echi-
nocandin, inhibiting the β-glucan synthase), clotrimazole (an azole, inhibiting the biosynthesis of ergosterols), 
amphotericin B (acting by binding chitin and forming pores membrane on the cell membrane), and calcofluor 
white (binding the chitin). The tested concentrations included the MIC for S. cerevisiae and three lower concen-
trations. In particular, the tested concentrations were (for each compound, the highest one is the MIC): 0.252 µg/
ml, 0.126 µg/ml, 0.063 µg/ml, and 0.0315 µg/ml for caspofungin; 3 µg/ml, 1.5 µg/ml, 0.75 µg/ml, and 0.375 µg/ml 
for clotrimazole; 1 µg/ml, 0.5 µg/ml, 0.25 µg/ml, and 0.125 µg/ml for amphotericin B; 25 µg/ml, 12.5 µg/ml, 6.25 µg/
ml, and 3.125 µg/ml for calcofluor white. Cells from an over-night culture of the BY4742 strain were inoculated in 
fresh YPD medium supplemented with the compounds at various combinations or with DMSO as control. Each 
test was carried out in three independent biological replicates. After 24 hours treatment at 28 °C with shaking, the 
Optical Density of cultures was measured, and the survival percentage was calculated as in equation [3].
=
×survival % OD 100
OD (3)c
t
where ODt is the OD of the treated culture and ODc is the OD of the control culture. Significant differences were 
searched between the effect of each treatment and the effect of the lethal 089 concentration (0.3 mM) by mean of 
2-tailed t-test. p-values were FDR corrected.
Aspergillus fumigatus RNA sequencing and analysis. A. fumigatus conidia were collected from solid 
Sabouraud cultures using PBS + 0.1% Tween, avoiding collection of mycelium fragments and hyphae. Conidia 
were then inoculated in MOPS buffered RPMI 1640 medium + 2% glucose at 2.5 × 105 conidia/ml concentration 
supplemented with either 0.1 mM 089 molecule or an equal volume of DMSO. After 4 hours of growth in static at 
37 °C, RNA was extracted from liquid nitrogen powder grounded samples with Trizol. Each treatment was carried 
out in three independent biological replicates. For each sample, one paired-end mRNA library with approxi-
mately 150 bp insert size was prepared using the TruSeq RNA Sample Preparation Kit v2 (Illumina). Libraries 
were sequenced on Illumina HiSeq 2000 lanes using 2 × 75 bp reads. The cluster generation kit was TruSeq PE 
Cluster Kit v3-cBot-HS, and the sequencing kit was TruSeq SBS Kit v3-HS. More than 40 million reads were 
generated for each sample. Raw reads were filtered and trimmed by using the IlluQC and TrimmingReads tools 
of the NGS QC Toolkit package45. The filtering process was carried out with the default options. The trimming 
was carried out with mild thresholds namely -q 5 -n 25. Alignment has been done by using tophat2 with the 
Aspergillus fumigatus A1160 reference genome sequence downloaded from NCBI (download date: 4 Nov 2016). 
The FPKMs (Fragments per Kilobase of transcript per Million mapped reads) were calculated to determine the 
expression level of each gene. The differential expression analysis was performed using the cuffdiff tool of the cuf-
flinks package45. DEGs were identified based on a false discovery rate (FDR) < 0.05. Gene Ontology (GO) enrich-
ment analysis was carried out on DEGs lists by using BiNGO46 and visualized with Cytoscape47. We compared the 
transcriptional profile of the 089 treatment with the transcriptional profiles of A. fumigatus cells at different stages 
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of the asexual cell cycle27. We then calculated the Manhattan distance among all the samples and genes and drew 
the cluster with the ward.D method. Read counts of identified sequences for each experiment are available in the 
ArrayExpress database (www.ebi.ac.uk/arrayexpress) under accession number E-MTAB-5309.
Target validation – effects on Aspergillus fumigatus isotropic growth rate and nuclear divi-
sion. The A1160 A. fumigatus strain was used to assess the effect of 089 on the fungal isotropic growth rate and 
nuclear division. The internalization of 089 drug granules within the fungal conidia/ germling was evaluated by 
observing microscopic auto fluorescent drug particles ~30 min post treatment. The localization of drug granules 
was assessed before and after washing twice the treated cells with PBS.
The volume and area of conidia treated with 0.4 mM 089 or with DMSO as control were measured using 
Imaris software (Bitplane, UK) of a confocal acquisition time lapse over 6 hours obtained using a Leica SP10 
microscope.
To count the number of nuclei of germinated A. fumigatus conidia, an A1160 A. fumigatus strain expressing 
the labelled Histone 1 protein (H1-sGFP) was used. Conidia were grown in Sabouraud medium for 6 hours at 
37 °C, then treated with 0.4 mM 089 or with DMSO as control. Images were captured every hour over a time 
course of 6 hours.
Dendritic cells (DC) binding assay. The experimental plan was approved by the local Ethical Committee 
of the Careggi hospital (Florence, Italy, Ref. n. 87/10), and informed consent was obtained from all the healthy 
donors. All methods were performed in accordance with the relevant guidelines and regulations. Peripheral 
Blood Mononucleated Cells (PBMCs) were isolated from buffy coat blood samples from healthy volunteers by 
Ficoll-Hypaque density gradient centrifugation. Monocytes were isolated from low density PBMCs by magnetic 
enrichment with anti-CD14 beads (Miltenyi Biotec). After isolation, monocytes were cultured in RPMI 1640 sup-
plemented with glutamine, penicillin and streptomycin, and 10% heat-inactivated fetal calf serum in the presence 
of GM-CSF (800 U/ml, Gentaur) and recombinant IL-4 (1000 U/ml, Gentaur) for 6 days to allow dendritic cells 
(DCs) differentiation48. S. cerevisiae, C. albicans and A. fumigatus cells were treated for 4 hours with sub-lethal 
concentrations of the 089 compound (0.2 mM). S. cerevisiae and C. albicans cells were treated in YPD at 28 °C 
with shaking, A. fumigatus cells were treated in MOPS-buffered RPMI medium at 37 °C in static. After the treat-
ment, cells were washed with sterile water and the labelling of S. cerevisiae, C. albicans and A. fumigatus was 
performed before exposure to DCs as previously described49. FITC-labelled fungi were added in a fungal cell:DC 
ratio of 5:1. After 30 minutes of incubation at 37 °C, cell-fungi conjugates were analysed by flow cytometry. The 
binding of DCs to fungi was measured by flow cytometry using a FACS Calibur instrument (BD Biosciences). 
DCs were labelled with anti-CD11c-PE to discriminate cells binding FITC-labelled yeast/spores particles from 
yeast/spores aggregates. Mann-Whitney test was used to evaluate the statistical significance of the results by com-
parison between treated and untreated strains.
Cytotoxicity on mammalian cells. K562 cells were grown in RPMI 1640 (Euroclone) supplemented with 
glutamine (Sigma), penicillin and streptomycin (SIGMA), and 10% heat-inactivated fetal calf serum (Hyclone). 
For toxicity assays, 3*105 cells/well were treated for 24 hours in 6-wells plates. Treatments were carried out with 
various concentrations of 089 (from 0.1 mM to 0.4 mM), ketoconazole (from 2.5 μM to 0.1 mM), or DMSO as 
control. Cell death induced by the treatments was assessed by the trypan blue exclusion technique. Survival per-
centage was evaluated as the number of live cells after the treatment with respect to the number of live cells after 
control treatment (cells grown without either the antifungals or DMSO). ANOVA statistics were used to evaluate 
differences among treatment effects.
Comparison of SWE1 sequences in yeasts and fungi. To support the possibility that the same gene 
is targeted by 089 in different yeasts and fungi, we compared the S. cerevisiae Swe1p sequence with the available 
sequences of homologues in other yeasts and fungi. The S. cerevisiae Swe1p sequence was downloaded from the 
SGD website (date of access 26 August 2017)50. Ortholog sequences in fungi were retrieved from the OrthoDB 
database, using the S. cerevisiae Swe1p sequence as query51. The so-obtained sequences were then aligned with 
Muscle. The Neighbor-joining tree was inferred from distances calculated as the number of substitutions as a 
proportion of the length of the alignment (excluding gaps) with the Simple Phylogeny tool at EMBL-EBI52 and 
drawn with figtree (http://tree.bio.ed.ac.uk/).
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